The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Immunogenicity of Therapeutic Protein Aggregates
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins
Fernandez-Escamilla, A.-M., Rousseau, F., Schymkowitz, J., & Serrano, L. (2004) · Nature Biotechnology · doi:10.1038/nbt1012 · Cited by 1,658
Chi, E. Y., Krishnan, S., Randolph, T. W., & Carpenter, J. F. (2003) · Pharmaceutical Research · doi:10.1023/a:1025771421906 · Cited by 1,379
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides
Conchillo-Solé, O., de Groot, N. S., Avilés, F. X., Vendrell, J., Daura, X., & Ventura, S. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-65 · Cited by 1,068
The Biochemistry and Cell Biology of Antigen Processing and Presentation
Germain, R. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.403 · Cited by 1,020
Protein aggregation: Pathways, induction factors and analysis
Mahler, H.-C., Friess, W., Grauschopf, U., & Kiese, S. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21566 · Cited by 901
The Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 717
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
(1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301204 · Cited by 577
Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Gelfand, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1009433 · Cited by 495
(2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.00607.x · Cited by 472
PASTA 2.0: an improved server for protein aggregation prediction
Walsh, I., Seno, F., Tosatto, S. C. E., & Trovato, A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku399 · Cited by 472
Intravenous Administration of Human γ‐Globulin*
Barandun, S., Kistler, P., Jeunet, F., & Isliker, H. (1962) · Vox Sanguinis · doi:10.1111/j.1423-0410.1962.tb03240.x · Cited by 386
Molecular determinants of immunogenicity: the immunon model of immune response.
Dintzis, H. M., Dintzis, R. Z., & Vogelstein, B. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.10.3671 · Cited by 383
The Zyggregator method for predicting protein aggregation propensities
Tartaglia, G. G., & Vendruscolo, M. (2008) · Chemical Society Reviews · doi:10.1039/b706784b · Cited by 349
Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K., Blue, J. T., Chou, D., Cromwell, M., Krause, H.-J., Mahler, H.-C., Meyer, B. K., et al. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22097 · Cited by 334
Self-citationNon‐native protein aggregation kinetics
Roberts, C. J. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21627 · Cited by 329
Classification and Characterization of Therapeutic Antibody Aggregates
Joubert, M. K., Luo, Q., Nashed-Samuel, Y., Wypych, J., & Narhi, L. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160457 · Cited by 316
Self-citationHow B cells capture, process and present antigens: a crucial role for cell polarity
Yuseff, M.-I., Pierobon, P., Reversat, A., & Lennon-Duménil, A.-M. (2013) · Nature Reviews Immunology · doi:10.1038/nri3469 · Cited by 307
Braun, A., Kwee, L., Labow, M. A., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 298
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Joubert, M. K., Hokom, M., Eakin, C., Zhou, L., Deshpande, M., Baker, M. P., Goletz, T. J., Kerwin, B. A., Chirmule, N., Narhi, L. O., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.330902 · Cited by 268
Self-citationImmunogenicity of protein aggregates—Concerns and realities
Wang, W., Singh, S. K., Li, N., Toler, M. R., King, K. R., & Nema, S. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.040 · Cited by 266
Forced Degradation of Therapeutic Proteins
Hawe, A., Wiggenhorn, M., van de Weert, M., Garbe, J. H. O., Mahler, H.-C., & Jiskoot, W. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22812 · Cited by 248
The PASTA server for protein aggregation prediction
Trovato, A., Seno, F., & Tosatto, S. C. E. (2007) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm042 · Cited by 243
Particles in Therapeutic Protein Formulations, Part 1: Overview of Analytical Methods
Zölls, S., Tantipolphan, R., Wiggenhorn, M., Winter, G., Jiskoot, W., Friess, W., & Hawe, A. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23001 · Cited by 230
Role of Aggregated Human Growth Hormone (hGH) in Development of Antibodies to hGH*
MOORE, W. V., & LEPPERT, P. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-4-691 · Cited by 220
Seidl, A., Hainzl, O., Richter, M., Fischer, R., Böhm, S., Deutel, B., Hartinger, M., Windisch, J., Casadevall, N., London, G. M., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0621-4 · Cited by 202
Chemical Modifications in Therapeutic Protein Aggregates Generated under Different Stress Conditions
Luo, Q., Joubert, M. K., Stevenson, R., Ketchem, R. R., Narhi, L. O., & Wypych, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.160440 · Cited by 199
Self-citationA critical review of methods for size characterization of non-particulate protein aggregates
Philo, J. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488815 · Cited by 196
Aggregation of Therapeutic Proteins
(2010) · Wiley eBooks · doi:10.1002/9780470769829 · Cited by 195
Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185
Ahmadi, M., Bryson, C. J., Cloake, E. A., Welch, K., Filipe, V., Romeijn, S., Hawe, A., Jiskoot, W., Baker, M. P., & Fogg, M. H. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1541-x · Cited by 177
Bachmann, M. F., Hengartner, H., & Zinkernagel, R. M. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251236 · Cited by 176
Udan, M. L. D., Ajit, D., Crouse, N. R., & Nichols, M. R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05001.x · Cited by 174
Immunogenicity of aggregates of recombinant human growth hormone in mouse models
Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21834 · Cited by 170
Rombach-Riegraf, V., Karle, A. C., Wolf, B., Sordé, L., Koepke, S., Gottlieb, S., Krieg, J., Djidja, M.-C., Baban, A., Spindeldreher, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086322 · Cited by 165
How we treat a hemophilia A patient with a factor VIII inhibitor
Kempton, C. L., & White, G. C. (2009) · Blood · doi:10.1182/blood-2008-06-160432 · Cited by 163
Filipe, V., Jiskoot, W., Basmeleh, A. H., Halim, A., Schellekens, H., & Brinks, V. (2012) · mAbs · doi:10.4161/mabs.22066 · Cited by 158
A Critical Review of Analytical Methods for Subvisible and Visible Particles
Narhi, L. O., Jiang, Y., Cao, S., Benedek, K., & Shnek, D. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109788488905 · Cited by 152
Self-citationAgrawal, N. J., Kumar, S., Wang, X., Helk, B., Singh, S. K., & Trout, B. L. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22705 · Cited by 144
Hermeling, S., Caetano, L. A., Damen, M. J. A., Slijper, M., Schellekens, H., Crommelin, D. J. A., & Jiskoot, W. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-8177-9 · Cited by 144
Barnard, J. G., Babcock, K., & Carpenter, J. F. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23415 · Cited by 137
Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies
Fehr, T. H., Bachmann, M. F., Bucher, E. M., Kalinke, U., Padova, F. E. D., Lang, A. B., Hengartner, H., & Zinkernagel, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.10.1785 · Cited by 135
The Immunogenicity of Antibody Aggregates in a Novel Transgenic Mouse Model
Bessa, J., Boeckle, S., Beck, H., Buckel, T., Schlicht, S., Ebeling, M., Kiialainen, A., Koulov, A. V., Boll, B., Weiser, T. W., et al. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1627-0 · Cited by 125
Protein particles: What we know and what we do not know
Ripple, D. C., & Dimitrova, M. N. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23242 · Cited by 121
van Beers, M. M. C., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0451-4 · Cited by 114
Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates
DEGROOT, A., MCMURRY, J., & MOISE, L. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.002 · Cited by 109
Immunogenicity of interferon beta: differences among products
Bertolotto, A., Deisenhammer, F., Gallo, P., & S�rensen, P. S. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1204-7 · Cited by 103
Specific inhibition of antibody production. I. Protein-over loading paralysis.
Dresser, D. W. (1962) · PubMed Central · Cited by 102
Adverse reactions following administration of human gamma globulin
Ellis, E. F., & Henney, C. S. (1969) · Journal of Allergy · doi:10.1016/0021-8707(69)90019-7 · Cited by 102
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice
Purohit, V. S., Middaugh, C. R., & Balasubramanian, S. V. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20529 · Cited by 92
van Beers, M. M. C., Jiskoot, W., & Schellekens, H. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0086 · Cited by 91
van Beers, M. M. C., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., & Jiskoot, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0172-0 · Cited by 90
THE ANTIGENICITY OF AGGREGATED AND AGGREGATE-FREE HUMAN GAMMA-GLOBULIN FOR RABBITS.
Biro, C. E., & GARCIA, G. (1965) · PubMed · Cited by 87
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks
Macdougall, I. C. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1087 · Cited by 81
Predictive tools for stabilization of therapeutic proteins
Voynov, V., Chennamsetty, N., Kayser, V., Helk, B., & Trout, B. L. (2009) · mAbs · doi:10.4161/mabs.1.6.9773 · Cited by 79
Freitag, A., Shomali, M., Michalakis, S., Biel, M., Siedler, M., Kaymakcalan, Z., Carpenter, J. F., Randolph, T. W., Winter, G., & Engert, J. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1472-6 · Cited by 73
Development of a Transgenic Mouse Model Immune Tolerant for Human Interferon Beta
Hermeling, S., Jiskoot, W., Crommelin, D. J. A., Bornæs, C., & Schellekens, H. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-4578-z · Cited by 72
Interferon immunogenicity: technical evaluation of interferon-alpha 2a.
Hochuli, E. (1997) · PubMed · Cited by 71
Clinical investigation of the immunogenicity of interferon-alpha 2a.
Ryff, J. ‐. (1997) · PubMed · Cited by 67
Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins
Fradkin, A. H., Carpenter, J. F., & Randolph, T. W. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22683 · Cited by 65
Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcγ receptors
Luo, Y., Lu, Z., Raso, S. W., Entrican, C., & Tangarone, B. S. (2009) · mAbs · doi:10.4161/mabs.1.5.9631 · Cited by 64
van Beers, M. M. C., Gilli, F., Schellekens, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22744 · Cited by 64
The Role of Soluble Aggregates in the Primary Immune Response of Mice to Human Gamma Globulin
Gamble, C. N. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000229829 · Cited by 63
Telikepalli, S. N., Shinogle, H. E., Thapa, P. S., Kim, J. H., Deshpande, M., Jawa, V., Middaugh, C. R., Narhi, L. O., Joubert, M. K., & Volkin, D. B. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24379 · Cited by 63
Self-citationComputational Methods to Predict Therapeutic Protein Aggregation
Buck, P. M., Kumar, S., Wang, X., Agrawal, N. J., Trout, B. L., & Singh, S. K. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_26 · Cited by 61
Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products
Bukofzer, S., Ayres, J. E., Chavez, A., Devera, M., Miller, J., Ross, D., Shabushnig, J. G., Vargo, S., Watson, H., & Watson, R. (2015) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2015.01037 · Cited by 59
Recombinant EPO production points the nephrologist should know
Jelkmann, W. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm392 · Cited by 59
Studies of aggregated gamma-globulin. II. Effect in vivo.
Christian, C. L. (1960) · PubMed · Cited by 56
Role of Hsp90 in Systemic Lupus Erythematosus and Its Clinical Relevance
Shukla, H. D., & Pitha, P. M. (2012) · Autoimmune Diseases · doi:10.1155/2012/728605 · Cited by 55
Bee, J. S., Goletz, T. J., & Ragheb, J. A. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23247 · Cited by 52
Bi, V., Jawa, V., Joubert, M. K., Kaliyaperumal, A., Eakin, C. M., Richmond, K., Pan, O. C.-C., Sun, J., Hokom, M. M., Goletz, T. J., et al. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23663 · Cited by 50
Self-citationPisal, D. S., Kosloski, M. P., Middaugh, C. R., Bankert, R. B., & Balu‐Iyer, S. V. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23091 · Cited by 48
Aggregation and Immunogenicity of Therapeutic Proteins
Filipe, V., Hawe, A., Schellekens, H., & Jiskoot, W. (2010) · Wiley eBooks · doi:10.1002/9780470769829.ch10 · Cited by 39
In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice
Filipe, V., Que, I., Carpenter, J. F., Löwik, C., & Jiskoot, W. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1154-9 · Cited by 39
Studies of Aggregated γ-Globulin
Christian, C. L. (1960) · The Journal of Immunology · doi:10.4049/jimmunol.84.1.117 · Cited by 39
Shomali, M., Tanriverdi, S., Freitag, A. J., Engert, J., Winter, G., Siedler, M., Kaymakcalan, Z., Carpenter, J. F., & Randolph, T. W. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24413 · Cited by 38
Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33
UV photodegradation of murine growth hormone: Chemical analysis and immunogenicity consequences
Fradkin, A. H., Mozziconacci, O., Schöneich, C., Carpenter, J. F., & Randolph, T. W. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.04.005 · Cited by 31
Christie, M., Torres, R. M., Kedl, R. M., Randolph, T. W., & Carpenter, J. F. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23794 · Cited by 29
Shomali, M., Freitag, A., Engert, J., Siedler, M., Kaymakcalan, Z., Winter, G., Carpenter, J. F., & Randolph, T. W. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23772 · Cited by 26
Weltzien, R. B., & Pachter, J. S. (2000) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(20000215)59:4<522::aid-jnr7>3.0.co;2-l · Cited by 24
Weksler, M. E., Bull, G., Schwartz, G. H., Stenzel, K. H., & Rubin, A. L. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106376 · Cited by 23
Sauerborn, M., van Beers, M. M. C., Jiskoot, W., Kijanka, G., Boon, L., Schellekens, H., & Brinks, V. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9783-z · Cited by 20
Lebrec, H. N., Hock, M. B., Sundsmo, J. S., Mytych, D. T., Chow, H. S., Carlock, L. L., Joubert, M. K., Reindel, J. F., Zhou, L., & Bussiere, J. L. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.822948 · Cited by 17
Self-citationDevelopment of a Transgenic Mouse Model to Study the Immunogenicity of Recombinant Human Insulin
Torosantucci, R., Brinks, V., Kijanka, G., Halim, L. A., Sauerborn, M., Schellekens, H., & Jiskoot, W. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23935 · Cited by 17
Kijanka, G., Sauerborn, M., Boon, L., Schellekens, H., & Brinks, V. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24170 · Cited by 9
Cited by
Factors affecting the physical stability (aggregation) of peptide therapeutics
Zapadka, K. L., Becher, F. J., Gomes dos Santos, A. L., & Jackson, S. E. (2017) · Interface Focus · doi:10.1098/rsfs.2017.0030 · Cited by 401
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Protein aggregation – Mechanisms, detection, and control
Wang, W., & Roberts, C. J. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.043 · Cited by 299
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Wasalathanthri, D. P., Rehmann, M. S., Song, Y., Gu, Y., Mi, L., Shao, C., Chemmalil, L., Lee, J., Ghose, S., Borys, M. C., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27461 · Cited by 177
Metadata
- Authors
- Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 105
- Issue
- 2
- Pages
- 417-430
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2281597363
- Cited by
- 529
- References
- 90
- FWCI
- 20.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.